Kalaris Therapeutics to Showcase Innovative Advances in Ophthalmology
Kalaris Therapeutics at the Stifel Ophthalmology Forum
PALO ALTO, Calif. — Kalaris Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company committed to developing groundbreaking therapies for common retinal diseases, has exciting news! The management team is set to join a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
Event Details
Here's what you need to know about the upcoming Fireside Chat:
- Type: Fireside Chat
- Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
- Date: Tuesday, May 27
- Time: 08:00 AM ET
- Location: You can join the event via the Webcast.
Post-event, a replay will be available on Kalaris Therapeutics’ Investor Relations webpage.
About Kalaris Therapeutics
Kalaris is at the forefront of the biopharmaceutical sector, concentrating on innovative treatments for significant retinal conditions. Their flagship therapy, TH103, is an investigational anti-VEGF agent that is capturing attention in the medical community. This unique therapy, designed by Dr. Napoleone Ferrara, is a fully humanized, recombinant fusion protein that serves as a decoy receptor for VEGF. Its formulation aims at potentially enhanced inhibition and retention within the retina, making it a promising solution for patients.
Currently, TH103 is undergoing assessment in a Phase 1 clinical trial targeting neovascular Age-related Macular Degeneration (nAMD), with intentions to further explore its efficacy against other retinal disorders such as Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO).
Contact Information
Interested parties can reach out to:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Phone: +1 212 915 2577
Email: cdavis@lifesciadvisors.com
Email: ir@kalaristx.com
Frequently Asked Questions
What is Kalaris Therapeutics?
Kalaris Therapeutics is a biopharmaceutical company working on treatments for retinal diseases, focusing on innovating therapies like TH103.
What event will Kalaris participate in?
Kalaris will take part in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
When is the Fireside Chat scheduled?
The Fireside Chat is set for Tuesday, May 27 at 08:00 AM ET.
Who are the speakers for the event?
The event features Andrew Oxtoby, CEO, and Matthew Feinsod, CMO of Kalaris Therapeutics.
How can I learn more about Kalaris's research?
You can visit their Investor Relations webpage for updates and information on their clinical trials and developments.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
